IRCT201502191556N74已完成2 期
Citichholine as adjuvant therapy in major depression: a randomized and double blind study
Tehran Medical Sciences University0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 50 years（—）
- 性别
- All
入选标准
- •a age between 18 – 50 years old; diagnoses are done on the basis of Diagnostic &
- •Statistical Mental Disorders (DSMD); HRSD score above14; signing informed consent.
- •Exclusion criteria: demise of a close relative; having other psychocognitive affliction; taking antidepressive & psychoactive drugs within the last two months; heart complication; thyroid complication; history of ECT (Electroconvulsive Therapy); alcohol & drug addiction; reaching menopause age; pregnancy and lactation.
排除标准
- 未提供
研究者
相似试验
招募中
3 期
Tipepidine as adjuvant therapt in major depressioMajor Depressive Disorder.Major depressive disorder, single episode, moderateF32.1IRCT20090117001556N122Tehran University of Medical Sciences,50
已完成
不适用
Microdose Antagonist Combination for Depression (MAC-D) Trial: combination of low dose naltrexone and flumazenil for treatment of major depressive disorderMental Health - DepressionMajor Depressive DisorderACTRN12621000310864Trexapharm Pty Ltd10
终止
2 期
The Antidepressant Efficacy of the Anticholinergic ScopolamineUnipolar DepressionBipolar DepressionNCT00369915National Institute of Mental Health (NIMH)17
已完成
不适用
Adjunctive acetaminophen therapy for Major DepressioDepressionJPRN-UMIN000007877Oizumi Hospital20
已完成
不适用
Pharmacological treatment of Depression: Phase II Lithium additioDepressionISRCTN75768415Erasmus Medical Center (The Netherlands)69